IMUX vs LLY vs ABBV vs GILD

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus 2. 4% for Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. (GILD) offers the better valuation at 18. 6x trailing P/E (480. 4x forward), making it the more compelling value choice. Analysts rate Immunic, Inc. (IMUX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Gilead Sciences, Inc.

(GILD) is the cheapest at 18. 6x versus AbbVie Inc. at 94. 8x. On forward P/E, AbbVie Inc. is actually cheaper at 16. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 1. 07x versus Gilead Sciences, Inc. 's 3. 60x — a reasonable growth-adjusted valuation.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +429.

1%, compared to -90. 8% for Immunic, Inc. (IMUX). Over 10 years, the gap is even starker: LLY returned +1485% versus IMUX's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus Immunic, Inc. 's 1. 80β — meaning IMUX is approximately 1222% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Gilead Sciences, Inc. (GILD) carries a lower debt/equity ratio of 109% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus 2. 4% for Gilead Sciences, Inc. (GILD). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 0. 0% for Immunic, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 0. 0% for IMUX. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 1. 07x versus Gilead Sciences, Inc. 's 3. 60x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, AbbVie Inc. (ABBV) trades at 16. 0x forward P/E versus 480. 4x for Gilead Sciences, Inc. — 464. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 26. 8% to $159. 56.

In this comparison, ABBV (2.

9% yield), GILD (2. 5% yield), LLY (0. 5% yield) pay a dividend. IMUX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Immunic, Inc. (IMUX) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1485%, IMUX: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMUX is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock; ABBV is a large-cap quality compounder stock; GILD is a mid-cap quality compounder stock. LLY, ABBV, GILD pay a dividend while IMUX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.